Iodohippurate

Summary

Iodohippurate (CHEMBL1681) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 305.07 Da · C9H8INO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1681
Name	Iodohippurate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8614
ChEBI	CHEBI:140408
Molecular formula	C9H8INO3
Molecular weight	305.07
InChIKey	CORFWQGVBFFZHF-UHFFFAOYSA-N

SMILES: C1=CC=C(C(=C1)C(=O)NCC(=O)O)I

IUPAC name: 2-[(2-iodobenzoyl)amino]acetic acid

ChEBI definition: A member of the class of benzamides resulting from the formal condensation of the carboxy group of 2-iodobenzoic acid with the amino group of glycine.

Also known as: SID29216137, SID170465302, SID144205379

Parent form; salt/anhydrous children: CHEMBL1200439, CHEMBL1200763, CHEMBL2104818

Patent coverage: 123 distinct patent families (383 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 382 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.05	Potency	8912	nM	CHEMBL_ACT_3626465

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02598674	Not specified	WITHDRAWN	Severe Sepsis in Children - IMPRESS-C
NCT02599844	Not specified	WITHDRAWN	Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).